Emergent BioSolutions Awarded Over $250 Million in Contract Modifications for Critical Medical Countermeasure Products

Emergent BioSolutions Inc. secures over $250 million in contract modifications from the U.S. Department of Health and Human Services for critical medical countermeasure products, including anthrax and smallpox vaccines. The contracts affirm Emergent as a trusted biodefense partner.